FMP
VolitionRx Limited
VNRX
AMEX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
0.49 USD
-0.00405 (-0.827%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
13.43k
90.03k
306.39k
775.3k
1.23M
2.34M
4.44M
8.43M
16M
30.36M
Revenue %
-
570.25
240.3
153.04
59.1
89.78
89.78
89.78
89.78
Ebitda
-19.23M
-25.69M
-29.24M
-34.04M
-25.58M
-2.34M
-4.44M
-8.43M
-16M
-30.36M
Ebitda %
-143.14k
-28.53k
-9.54k
-4.39k
-2.07k
-100
-100
-100
-100
Ebit
-20.27M
-26.83M
-30.43M
-35.46M
-26.92M
-2.34M
-4.44M
-8.43M
-16M
-30.36M
Ebit %
-150.89k
-29.8k
-9.93k
-4.57k
-2.18k
-100
-100
-100
-100
Depreciation
1.04M
1.15M
1.19M
1.41M
1.34M
2.34M
4.44M
8.43M
16M
30.36M
Depreciation %
7.75k
1.27k
387.88
182.29
108.55
100
100
100
100
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
19.44M
20.58M
10.87M
20.73M
3.26M
2.34M
4.44M
8.43M
16M
30.36M
Total Cash %
144.75k
22.86k
3.55k
2.67k
264.65
100
100
100
100
Receivables
7.12k
12.51k
72.61k
242.62k
110.57k
612.56k
1.16M
2.21M
4.19M
7.95M
Receivables %
52.99
13.89
23.7
31.29
8.96
26.17
26.17
26.17
26.17
Inventories
303.18k
598.37k
784.92k
-
-
1.4M
2.67M
5.06M
9.6M
18.22M
Inventories %
2.26k
664.59
256.18
-
-
60
60
60
60
Payable
1.54M
1.54M
3.04M
3.21M
2.77M
2.34M
4.44M
8.43M
16M
30.36M
Payable %
11.46k
1.71k
993.17
414.2
224.25
100
100
100
100
Cap Ex
-1.94M
-973.56k
-1.57M
-1.08M
-277.5k
-1.98M
-3.75M
-7.12M
-13.52M
-25.66M
Cap Ex %
-14.45k
-1.08k
-512.47
-139.78
-22.5
-84.5
-84.5
-84.5
-84.5
Weighted Average Cost Of Capital
Price
0.49
Beta
Diluted Shares Outstanding
86.53M
Costof Debt
18.22
Tax Rate
After Tax Cost Of Debt
18.22
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
1.87M
Total Equity
42.4M
Total Capital
44.26M
Debt Weighting
4.22
Equity Weighting
95.78
Wacc
9.62
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
13.43k
90.03k
306.39k
775.3k
1.23M
2.34M
4.44M
8.43M
16M
30.36M
Ebitda
-19.23M
-25.69M
-29.24M
-34.04M
-25.58M
-2.34M
-4.44M
-8.43M
-16M
-30.36M
Ebit
-20.27M
-26.83M
-30.43M
-35.46M
-26.92M
-2.34M
-4.44M
-8.43M
-16M
-30.36M
Tax Rate
-
-
-
-
-
-
-
-
-
-
Ebiat
-20.35M
-26.81M
-30.1M
-35.1M
-26.92M
-2.33M
-4.42M
-8.39M
-15.93M
-30.23M
Depreciation
1.04M
1.15M
1.19M
1.41M
1.34M
2.34M
4.44M
8.43M
16M
30.36M
Receivables
7.12k
12.51k
72.61k
242.62k
110.57k
612.56k
1.16M
2.21M
4.19M
7.95M
Inventories
303.18k
598.37k
784.92k
-
-
1.4M
2.67M
5.06M
9.6M
18.22M
Payable
1.54M
1.54M
3.04M
3.21M
2.77M
2.34M
4.44M
8.43M
16M
30.36M
Cap Ex
-1.94M
-973.56k
-1.57M
-1.08M
-277.5k
-1.98M
-3.75M
-7.12M
-13.52M
-25.66M
Ufcf
-20.02M
-26.94M
-29.23M
-33.99M
-26.17M
-4.3M
-3.44M
-6.54M
-12.4M
-23.54M
Wacc
9.62
9.62
9.62
9.62
9.62
Pv Ufcf
-3.92M
-2.87M
-4.96M
-8.59M
-14.87M
Sum Pv Ufcf
-35.21M
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
9.62
Free Cash Flow T1
-24.01M
Terminal Value
-315.16M
Present Terminal Value
-199.12M
Intrinsic Value
Enterprise Value
-234.33M
Net Debt
-1.4M
Equity Value
-232.94M
Diluted Shares Outstanding
86.53M
Equity Value Per Share
-2.69
Projected DCF
-2.69 1.182%
